



Société anonyme au capital de 1 611 465,60 euros
Siège social : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ

ABL Diagnostics announces a new collaboration for CDL Pharma on two European clinical trials in digestive oncology

Woippy, December 1st, 6:00 PM – ABL Diagnostics announces a new collaboration for CDL Pharma to support the deployment of its services in two large-scale European clinical trials: COLOSOTO and FRUQUITAS, promoted by the Fédération Francophone de Cancérologie Digestive (FFCD). These studies, conducted over several years and involving dozens of centers across France and Europe, require rigorous logistical and administrative organization.

CDL Pharma, an expert in clinical trial management and biological sample logistics, will handle kit design, flow planning, and administrative follow-up for the studies. ABL Diagnostics supports this initiative to ensure efficient coordination and execution in compliance with international standards.

An industrial and economic dynamic

This collaboration aims to strengthen the competitiveness of both entities in the European clinical trial services market. By combining their expertise, ABL Diagnostics and CDL Pharma seek to optimize resources through centralized organization, reduce timelines and costs through better anticipation of needs, and provide sponsors with a comprehensive and coherent solution that enhances project value.

“As announced last October, we are pleased to have supported CDL Pharma since July 1, 2025, in the development of its activities and in structuring ambitious projects such as those now launched in digestive oncology. This collaboration with the FFCD is part of a broader dynamic that strengthens, with each new study, our technological and organizational capabilities, while opening new growth opportunities for ABL Diagnostics and the entire group,” said Dr Chalom Sayada, CEO of ABL Diagnostics.

Study details on the FFCD website: :

- COLOSOTO (PRODIGE 107 – ENGIC 01):

https://www.ffcd.fr/index.php?option=com_content&view=article&id=83&etude=00166&Itemid=144

- FRUQUITAS (PRODIGE 114 – ENGIC 06)

https://www.ffcd.fr/index.php?option=com_content&view=article&id=83&etude=00173&Itemid=144

About ABL Diagnostics (ABLD)

ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:

- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek®.

ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:

- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.

Integrated Solutions

- Real-time syndromic PCR tests
- Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
- MediaChek® – Clinical Sample Collection Kits.

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

Contact

ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ	Tel : +33 (0)7 83 64 68 50 Email : info@abldiagnostics.com https://www.abldiagnostics.com/
--	---